Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Drug Discovery & Development » BioFocus Extends Drug Screening Pact with Lilly

BioFocus Extends Drug Screening Pact with Lilly

Feb 25, 2009

NEW YORK (GenomeWeb News) – BioFocus DPI said this week that it has extended a drug screening pact with drug giant Eli Lilly until the end of 2009.

Under terms of the deal, BioFocus, which is the service division of Galapagos, will identify active compounds by screening Lilly's library of drug candidates. BioFocus has been conducting research work on compounds that target specific cellular signal transduction pathways for Lilly since March 2005.

Financial and other terms of the collaboration were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Russia Vaccine Approval Raises Concerns

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

Numbers Needed

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

PNAS Papers on Sarcoma Fusion Effects, Transfer RNA Changes in Colon Cancer, TB-T2D Interactions

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Move Away From Basic Research?

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
27
Featured Webinar

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.

Sep
09
Featured Webinar

Spatially Resolved Transcriptomics: The Landscape of Tools for Spatial Gene Expression

Sponsored by
10x Genomics

Recent advances in spatially resolved transcriptomics have greatly expanded the knowledge of complex multicellular biological systems. 

Sep
10
Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Sponsored by
Genecentric

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

What's Popular?

In Drug Discovery & Development

  1. Broad Institute, One Mind Win $518K Grant for Alzheimer's Disease Research

  2. Caris Life Sciences, Elevation Oncology Partner on Patient Enrollment for Tumor-Agnostic Drug Trial

  3. Singapore's Avatamed Raises $1M in Seed Funding

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.